Adherence Interventions to Improve HIV Treatment Outcomes David R Bangsberg Massachusetts General Hospital Center for Global Health Harvard Medical School.

Slides:



Advertisements
Similar presentations
Coordinating Care Across Funded Providers to Support Retenion in Care: The In+Care Campaign in RI. Aadia Rana, MD Assistant Professor of Medicine Miriam.
Advertisements

Intervening to Improve Adherence – What do we Know? Conall O’Cleirigh, Ph.D. Associate Director Behavioral Medicine, Department of Psychiatry.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Integrating Evidence-Based Practice Into QI to Improve Patient Outcomes in HIV: Viral Load Suppression Victoria Lieb, ACRN, MPH; Carla Rossi, MD; Jaime.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Adherence to ART Bannet Ndyanabangi Copenhagen, February 2006.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.
Conditional Cash Transfers and Contingency Management Strategies in Substance Users Mark Hull MD, MHSc, FRCPC Clinical Assistant Professor, University.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
1 Assessing and Improving ARV Adherence HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Effects of an HIV/AIDS peer prevention intervention on sexual and injecting risk behaviors among injecting drug users (IDUs) and their risk partners in.
Global HIV Resistance: The Implications of Transmission
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Adherence and Resistance to HIV Antiretroviral Therapy David Bangsberg, MD, MPH Massachusetts General Hospital Harvard Medical School Harvard Initiative.
Effects of a Mobile Phone Short Message Service (SMS) on Antiretroviral Treatment Adherence in Kenya (WelTel Kenya1): A Randomized Trial Jesse Coleman.
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Medication Adherence: What Can We Do to Help Patients Stick to Therapy Lois Eldred, DrPH, MPH Special Projects of National Significance HIV/AIDS Bureau,
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Immigration Removal Centres and HIV Clinical Care Jane Anderson Homerton University Hospital NHS Foundation Trust.
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
Addressing adherence challenges – what does the evidence say? Dr Catherine Orrell Desmond Tutu HIV Foundation November 2013.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Maintenance therapy with Trizivir® after 6 months induction with Trizivir® plus either efavirenz or lopinavir/r in naïve patients. Trizefal study J. Mallolas*
02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
Assessing Your Clients for Adherence: A Real World Approach Sharon Mannheimer, MD Harlem Hospital Center Treatment Adherence Network Meeting February 27,
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
Michael J. Mugavero, MD, MHSc Associate Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama Elements of the Care Continuum FORMATTED:
Drug Adherence and Strategies for Compliance Assist. Prof. Dr. Memet IŞIK Ataturk University Medical Faculty Department of Family Medicine
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Adherence to HAART. Adherence Summary Adherence is the Achilles Heel of HAART Adherence requires education, a shared negotiation, & the optimal regimen.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Center for Studies of Addiction, University of Pennsylvania, USA
Treatment-Naïve Adults
Title Factors associated with viral suppression among adolescents living with HIV in Cambodia “No conflicts of interest to declare”
Adetunji Adejumo, MD; Cynthia Lee MA; Sharon Mannheimer, MD
Elements of the Care Continuum
Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.
EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.
Switch to LPV/r monotherapy
Comparison of NNRTI vs PI/r
Switch to LPV/r monotherapy
Comparison of NNRTI vs NNRTI
Switch to RAL-containing regimen
Switch to ATV/r monotherapy
Switch to LPV/r monotherapy
HIV Resistance in the Context of PrEP
Presentation transcript:

Adherence Interventions to Improve HIV Treatment Outcomes David R Bangsberg Massachusetts General Hospital Center for Global Health Harvard Medical School Harvard Initiative for Global Health June, 2010

Outline Adherence goals Simple stuff to improve adherence RCT intervention summary RCT intervention highlights Cost effectiveness of ART adherence interventions Future directions in adherence interventions

MEMS Adherence and Viral Suppression Paterson DL, et al. Ann Intern Med. 2000;133:  

NNRTI Lead to Better Viral Suppression (<400 copies/ml) than Unboosted PIs at Moderate Electronic Medication Monitor Adherence n=65 p=0.01 Bangsberg CID 2006 : 43:939-41

Stopping drugs with different half lives Time (hours) Drug concentration Zone of potential replication IC 90 IC 50 Last Dose Day 1 Day 2 MONOTHERAPY S. Taylor et al. 11th CROI Abs 131

NNRTI Resistance and Treatment Discontinuation Parienti et al CID 2004:38: No. patients at Risk ≤1 drug holiday >= 2 drug holidays

The Risk of Virologic Failure Decreases with Duration of Continuous Viral Suppression in 221 Suppressed Patients M. Rosenblum et al PLOS One 2009

Adherence Goals Goals –Prevent HIV-related mortality –Prevent evolution of drug resistance Sustain adherence above 70% Prevent treatment interruptions on NNRTI based therapy –Adherence is important all the time, but especially important after initiating treatment

Outline Adherence goals Simple stuff to improve adherence RCT intervention summary RCT intervention highlights Cost effectiveness of ART adherence interventions Future directions in adherence interventions

Pill box organizers improve adherence and reduce viral load ML Petersen et al Clin Infect Dis Oct 1;45(7): MSM Estimator Difference in % Adherence 95% CIDifference in Log VL 95% CIOR VL<400 95% CI G-Comp 4.5% (2.0, 7.0) (0.08, 0.60) 1.81 (1.25, 2.62) IPTW 4.1% (0.0, 8.3) (0.05, 0.69) 1.91 (1.27, 2.90) Double Robust 4.1% (1.1, 7.1) (0.09, 0.63) 1.91 (1.27, 2.90) 4% better adherence 1.9 odds better viral suppression $5.00/pill box: extremely cost-effective intervention Should be standard-of-care

A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in homeless and marginally housed individuals. Bangsberg et al CROI 2010 Unannounced pill count adherenceProportion VL<400 c/ml

Outline Adherence goals Simple stuff to improve adherence RCT intervention summary RCT intervention highlights Cost effectiveness of ART adherence interventions Future directions in adherence interventions

RCT Adherence Interventions Meta-analyses/Systematic reviews J Simoni et al JAIDS 2006 Dec 1;43 Suppl 1:S23-35 Amico et al JAIDS : Simoni, Amico et al Curr HIV/AIDS Rep (2010) 7:44–51

95% Adherence at First Follow-up J Simoni et al JAIDS 2006 Dec 1;43 Suppl 1:S23-35 Study Intervention Control OR (95% CI) (n/N) (n/N) DiIorio 8/8 6/99.29 (3.15, 27.35) Knobel 46/60 58/ (2.32, 3.76) Margolin 23/3712/ (1.03, 7.28) Weber 21/31 12/ (0.78, 7.52) Safren-life 16/30 8/ (1.42, 3.74) Remien 30/86 18/ (1.82, 2.90) Rathbun 6/16 4/ (1.16, 3.25) Pradier 75/64 62/ (1.56, 2.36) Tuldra 37/40 35/ (1.05, 2.95) Murphy 14/1711/ (0.69, 2.35) Andrade 14/32 12/ (0.44, 3.53) Rawlings 15/5118/ (0.88, 1.46) Samet 33/53 40/ (0.74, 1.24) Goujard 86/101 73/ (0.71, 1.25) Jones 40/92 40/ (0.43, 1.43) Rigsby 4/15 4/ (0.43, 1.33) Safren-pager 1/34 1/ (.02, 19.33) Rotheram 15/19 12/ (0.14, 0.67) Overall 484/ / (1.16,1.94) OR=1.5 ( )

Study Intervention Control OR (95% CI) (n/N) (n/N) Rathbun 16/16 12/ (4.81, 37.79) Smith 7/115/ (1.64, 5.14) Tuldra 22/28 17/ (1.33, 3.07) Knobel 39/60 60/ (1.24, 1.94) Pradier 79/123 65/ (1.27, 1.81) Goujard 49/77 37/ (0.96, 1.54) Rawlings 53/66 43/ (0.88, 1.46) Remien 37/86 39/ (0.89, 1.33) Samet 19/31 24/ (0.69, 1.34) Andrade 10/29 11/ (0.60, 1.25) Rigsby 3/15 3/ (0.44, 1.58) Margolin 11/25 11/ (0.43, 0.97) Weber 27/29 23/ (0.25, 1.35) Rotheram 4/9 2/ (0.21, 1.29) Overall 376/ / (.99, 1.59) Undetectable VL Post-Intervention J Simoni et al JAIDS 2006 Dec 1;43 Suppl 1:S23-35 OR 1.25 ( )

Efficacy of Antiretroviral Therapy Adherence Interventions: A Research Synthesis of Trials, 1996 to 2004 Amico et al JAIDS : Intervention effect stronger for studies that selected for incomplete adherence

Simoni and Amico Synthesis Interactive, open-ended, and multidisciplinary –pharmacist, case manager, physician, family/partner –education, behavioral skills, motivation/cognition expectations, reminders Multiple sessions Greatest effect in the least adherent Doesn’t last much beyond the intervention More recent interventions may be less likely to find virologic benefit

Outline Adherence goals Simple stuff to improve adherence RCT intervention summary RCT intervention highlights Cost effectiveness of ART adherence interventions Future directions in adherence interventions

92.8% 88.9% Interventions Prevent a Decline in Adherence Cognitive behavior intervention on adherence to ARV therapy Weber et al Antiviral Therapy 2004:9:85

Couple-focused support to improve HIV medication adherence: a randomized controlled trial Remien et al AIDS 2005:19: Serodiscordant couple >6 months 2 week MEMS adherence monitor screen –Eligible if <80% adherence Four minutes sessions –Structured discussion and education about adherence to identify barriers –Problem solving to overcome barriers –Couple communication exercises to optimize partner support MEMS Adherence and VL over 6 months

Proportion Adherent at 3 Levels Couple-focused support to improve HIV medication adherence: a randomized controlled trial Remien et al AIDS 2005:19:

ACTG 731: A Multi-site Randomized Controlled Trial of Weekly Nursing Telephone Support to Improve ARV Adherence Reynolds et al JAIDS 2008 Content: –Patient-centered—elicits patient perspective and addresses patient’s biological, social and cultural realities Mode: –Fits clinical environment of care –Provides “safety feature” in context of home –Suitable to persons with lower levels of literacy –Takes advantage of training of nurses who are widely available in different clinic settings

ACTG 731. Nurse-Delivered Telephone Intervention A better overall treatment effect was observed in the treated (telephone group) (p = 0.023) in comparison with standard care Reynolds et al., JAIDS, 2008

Home Visits to Improve Adherence to Highly Active Antiretroviral Therapy: A Randomized Controlled Trial Williams et al JAIDS 2006:42: RCT community based home visits vs standard care –Paulo Freire: True learning occurs through dialogue and participation among equals –24 home visits over 12 months: identify concerns, individuals, social factors –Outcome: MEMS adherence and HIV VL

Home Visits to Improve Adherence to Highly Active Antiretroviral Therapy: A Randomized Controlled Trial Williams et al JAIDS 2006:42: Proportion MEMS Adherence >90% No difference in VL or CD4 between groups (54 vs 52% ND)

Cognitive Behavioral Therapy For Improving Adherence and Depression Safren et al Health Psychology in Press 2 Arm, cross-over design comparing 12 sessions of CBT-AD to a single session of adherence counseling Participants: 45 randomized, 42 completers with DSM-IV diagnosable depression CBT-AD resulted in improved adherence (MEMS) and depression at three months, and maintains were gained at 6 and 12 months. ITT ANCOVA, F(1,42) = 21.94, p<.0001, Effect size (Cohen d) = 1.0 Three-month (acute) outcome depicted above Pattern of results similar ITT and completer analyses

Directly Assisted Antiretroviral Therapy Not effective for “all-comers” (Wohl CID 2006, Ford Lancet 2009) Effective in active drug users and methadone maintenance (Macalino AIDS 2007, Altice CID 2007, Lucas CID 2004) Does not last beyond intervention Exit strategy and relapse remain a challenge

Outline Adherence goals Simple stuff to improve adherence RCT intervention summary RCT intervention highlights Cost effectiveness of ART adherence interventions Future directions in adherence interventions

Adherence Interventions are Cost Effective Goldie et al AJM 2003

Outline Adherence goals Simple stuff to improve adherence RCT intervention summary RCT intervention highlights Cost effectiveness of ART adherence interventions Future directions in adherence interventions

Duration of MEMS Defined Treatment Interruption and Probability of NNRTI Resistance Parienti and Bangsberg PLOS One Controls O Cases Estimated 95% confidence interval Longer interval of treatment discontinuation in days Estimated probability of viral control

Real-time Adherence Monitoring Bangsberg and Deeks Annal Int Med 2010

Adherence Intervention Summary Goals of adherence are changing –>80% and no sustained interruptions –Preventing the decline in adherence Most effective interventions: educational, motivational, open-ended, interactive sessions to identify barriers and develop behavioral skills Intensive interventions for high risk patients Real-time monitoring: reactive response to proactive prevention of treatment resistant failure